Marie Le Moigne1,2, Mélanie Saint-Jean1,2, Adam Jirka3, Gaëlle Quéreux1,2, Lucie Peuvrel1,2, Anabelle Brocard1,2, Aurélie Gaultier4, Amir Khammari1,2, Dominique Darmaun3, Brigitte Dréno5,6,7. 1. Dermato-cancerology Unit, University Hospital Hôtel-Dieu, Nantes, France. 2. Inserm, UMR 892, CIC Biotherapy Inserm 0503, Nantes, France. 3. Nutrition Support Team IMAD, DHU 2020, University Hospital Hôtel-Dieu, Nantes, France. 4. SEB, University Hospital Hôtel-Dieu, Nantes, France. 5. Dermato-cancerology Unit, University Hospital Hôtel-Dieu, Nantes, France. brigitte.dreno@wanadoo.fr. 6. Inserm, UMR 892, CIC Biotherapy Inserm 0503, Nantes, France. brigitte.dreno@wanadoo.fr. 7. Dermato-cancerology Unit, University Hospital Hôtel-Dieu, Place Alexis Ricordeau, 44093, Cedex 01, France. brigitte.dreno@wanadoo.fr.
Abstract
PURPOSE: Whereas vismodegib is effective in the treatment of locally advanced/metastatic basal cell carcinoma, dysgeusia and weight loss are common side effects of such treatment. The main objective of this study was to monitor the nutritional status of vismodegib-treated patients. Secondary objective was to assess the incidence of dysgeusia and the benefit of early nutritional management. METHODS: This prospective study included all patients who started vismodegib between October 2011 and May 2013 at Nantes University Hospital. Prior to July 2012, patients treated with vismodegib had not received any specific nutritional management (Historical cohort). Body weight and presence of dysgeusia were recorded monthly. Patients treated after July 2012 (Nutrition cohort) were evaluated by a physician of the Nutrition Support Unit and received dietary counseling at vismodegib initiation. A standardized nutritional management protocol was initiated in case of significant weight loss. RESULTS: Forty-five patients (21 and 24 in the Nutrition and Historical cohort, respectively) were enrolled. In the Nutrition cohort, five patients (24 %) were undernourished at vismodegib initiation, and the 6-month cumulative incidence of dysgeusia was 71 %. Eight patients (38 %) and 13 patients (54 %) had a weight loss greater than 5 % in the Nutrition and Historical cohort, respectively (p = 0.3727). CONCLUSION: The results of this pilot study suggest the benefit of early nutritional screening. The potential benefit of nutritional support in this setting warrants further investigation.
PURPOSE: Whereas vismodegib is effective in the treatment of locally advanced/metastatic basal cell carcinoma, dysgeusia and weight loss are common side effects of such treatment. The main objective of this study was to monitor the nutritional status of vismodegib-treated patients. Secondary objective was to assess the incidence of dysgeusia and the benefit of early nutritional management. METHODS: This prospective study included all patients who started vismodegib between October 2011 and May 2013 at Nantes University Hospital. Prior to July 2012, patients treated with vismodegib had not received any specific nutritional management (Historical cohort). Body weight and presence of dysgeusia were recorded monthly. Patients treated after July 2012 (Nutrition cohort) were evaluated by a physician of the Nutrition Support Unit and received dietary counseling at vismodegib initiation. A standardized nutritional management protocol was initiated in case of significant weight loss. RESULTS: Forty-five patients (21 and 24 in the Nutrition and Historical cohort, respectively) were enrolled. In the Nutrition cohort, five patients (24 %) were undernourished at vismodegib initiation, and the 6-month cumulative incidence of dysgeusia was 71 %. Eight patients (38 %) and 13 patients (54 %) had a weight loss greater than 5 % in the Nutrition and Historical cohort, respectively (p = 0.3727). CONCLUSION: The results of this pilot study suggest the benefit of early nutritional screening. The potential benefit of nutritional support in this setting warrants further investigation.
Entities:
Keywords:
Dysgeusia; Malnutrition; Nutritional management; Vismodegib; Weight loss
Authors: Allan J Hovan; P Michele Williams; Peter Stevenson-Moore; Yula B Wahlin; Kirsten E O Ohrn; Linda S Elting; Fred K L Spijkervet; Michael T Brennan Journal: Support Care Cancer Date: 2010-05-22 Impact factor: 3.603
Authors: J P Baker; A S Detsky; D E Wesson; S L Wolman; S Stewart; J Whitewell; B Langer; K N Jeejeebhoy Journal: N Engl J Med Date: 1982-04-22 Impact factor: 91.245
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Barbara J Stewart-Knox; Ellen E A Simpson; Heather Parr; Gordon Rae; Angela Polito; Federica Intorre; Maud Andriollo Sanchez; Natalie Meunier; Jacqueline M O'Connor; Giuseppe Maiani; Charles Coudray; J J Strain Journal: Br J Nutr Date: 2007-07-26 Impact factor: 3.718
Authors: Anne Lynn S Chang; James A Solomon; John D Hainsworth; Leonard Goldberg; Edward McKenna; Bann-mo Day; Diana M Chen; Glen J Weiss Journal: J Am Acad Dermatol Date: 2013-11-01 Impact factor: 11.527
Authors: Mario E Lacouture; Brigitte Dréno; Paolo Antonio Ascierto; Reinhard Dummer; Nicole Basset-Seguin; Kate Fife; Scott Ernst; Lisa Licitra; Rogerio I Neves; Ketty Peris; Susana Puig; Jonas Sokolof; Aleksandar Sekulic; Axel Hauschild; Rainer Kunstfeld Journal: Oncologist Date: 2016-08-10